The Epigenetics (R)evolution
This article was originally published in Start Up
Executive Summary
Constellation and EpiZyme are poised to become dominant players in the unfolding field of epigenetics, an area of biology replete with novel, interesting targets and broad therapeutic potential. The two companies have adopted similar and until now stealthy strategies, aimed at parlaying a platform of novel products into a quick and lucrative exit.